This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratner, M. Fecal transplantation poses dilemma for FDA. Nat Biotechnol 32, 401–402 (2014). https://doi.org/10.1038/nbt0514-401
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0514-401
This article is cited by
-
Seres's pioneering microbiome drug fails mid-stage trial
Nature Biotechnology (2016)
-
Microbial cocktails join fecal transplants in IBD treatment trials
Nature Biotechnology (2015)
-
Clostridium difficile Infection: Current and Emerging Therapeutics
Current Treatment Options in Infectious Diseases (2015)
-
OpenBiome remains open to serve the medical community
Nature Biotechnology (2014)